This era has witnessed antibodies coming of age as therapeutics, delivering interesting results in the treatment of several major diseases, including autoimmune, cardiovascular, and infectious diseases, cancer, and inflammation. The recent advancements in antibody engineering technologies have enabled a diversity of antibody formats with specific functional features. Thus, these variability and complexity call for extensive and comprehensive characterization studies in order to ensure safety and efficacy. —
Creative Biolabs, an experienced expert in antibody production, has assembled a group of scientists who are professionals in non-IgG (mainly IgA, IgE, and IgM) antibody development, and is now offering non-IgG therapeutic antibody characterization services.
Because of the heterogeneities induced by modifications throughout distinct steps of manufacture and purification, antibody characterization can be a crucial component in biopharmaceutical development. At Creative Biolabs, scientists are skilled at using a variety of methods to assess the quality, quantity, as well as function of therapeutic non-IgG antibodies.
The cutting-edge technologies for IgA, IgE, and IgM therapeutic antibody characterization cover antibody titration and quantization by ELISA, high-performance liquid chromatography (HPLC) analysis, SDS-PAGE assay, intact mass determination by mass spectrometry of heavy and light chains, western blot (WB) assay, epitope binning, affinity ranking, EC50 and IC50, N- and C-terminal sequencing of the heavy and light chains by Edman degradation and matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS), cross-reactivity, and cell-based screening.
“As extensive efforts have been made in optimizing IgG antibodies for therapeutic use, we noticed that non-IgG antibodies also have great underdeveloped potential. For example, IgA has been proved to be even more effective in tumor cell killing and potently active against several pathogens, such as polio-virus, influenza virus, and the threatening SARS-CoV-2,” said a senior scientist in the non-IgG antibody development team, “we hope that our IgA antibodies characterization and other IgA services can facilitate related research to unleash its full potential.”
Looking for a reliable partner for your non-IgG antibody program? Creative Biolabs will be the right choice. Learn more from the official website: https://non-igg-ab.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is skilled at providing non-IgG therapeutic antibody development services with the support of the cutting-edge Antibody GlycoOpitimize Platform and Expression System Platform. The one-stop services range from non-IgG antibody discovery, engineering, production and purification, to characterization and PK/PD evaluation.
Release ID: 89053433